Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases

  • ACS Med Chem Lett. 2016 Nov 30;8(1):118-123. doi: 10.1021/acsmedchemlett.6b00438.
Montse Erra  1 ,  Joan Taltavull  1 ,  Angelique Gréco  1 ,  Francisco Javier Bernal  1 ,  Juan Francisco Caturla  1 ,  Jordi Gràcia  1 ,  María Domínguez  1 ,  Mar Sabaté  1 ,  Stéphane Paris  1 ,  Salomé Soria  1 ,  Begoña Hernández  1 ,  Clara Armengol  1 ,  Judit Cabedo  1 ,  Mónica Bravo  1 ,  Elena Calama  1 ,  Montserrat Miralpeix  1 ,  Martin D Lehner  1
Affiliations
  • 1. Medicinal Chemistry and Screening, Pharmacokinetics and Metabolism, Systems Biology, and Respiratory Therapeutic Area, Almirall R&D , Barcelona 08980, Spain.
PMID: 28105286 DOI: 10.1021/acsmedchemlett.6b00438
Abstract

The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases. Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described. The main challenge of the optimization process was to identify an orally available compound with a good pharmacokinetic profile in preclinical species that predicted a suitable dosing regimen in humans. Structure-activity relationships and structure-property relationships are discussed. This medicinal chemistry exercise led to the identification of LAS191954 as a candidate for clinical development.

Keywords
PI3Kδ inhibitor; Phosphoinositide-3-kinase delta inhibitor; autoimmune diseases; inflammatory diseases; lead optimization; structure−activity relationship.
Products